Terms ending in 2040
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,459,916 | Substituted Indazoles Useful for Treatment and Prevention of Allergic And/Or Inflammatory Diseases in Animals In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 11,667,675 | Masp Inhibitory Compounds and Uses Thereof In force · High confidence | Bayer Aktiengesellschaft | In force | High confidence | |
| US 12,503,491 | Masp Inhibitory Compounds and Uses Thereof In force · Medium confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 11,944,690 | Formulation of Contrast Media and Process of Preparation Thereof In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 12,059,472 | Prodrugs of Cytotoxic Active Agents Having Enzymatically Cleavable Groups In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,998,539 | Substituted Aminoquinolones as Dgkalpha Inhibitors for Immune Activation In force · Medium confidence | Deutsches Krebsforschungszentrum | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.